Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03463824
Other study ID # HM20014058
Secondary ID 1R01HD088417-01A
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2019
Est. completion date October 14, 2023

Study information

Verified date February 2024
Source Virginia Commonwealth University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will measure the effects of interactive, whole-body video games on movement behavior in people with chronic low back pain.


Description:

A fundamental clinical problem in individuals with chronic low back pain is the significant alteration in movement patterns that restrict lumbar spine motion. This restriction of lumbar motion is particularly evident in patients with kinesiophobia; that is, a fear of movement due to possible injury or reinjury. For chronic back pain patients with kinesiophobia it is critical to develop an effective intervention to increase spine motion while minimizing concerns of pain and harm. Accordingly, we have developed a innovative video games that track whole-body motion and are designed to encourage spinal flexion while reducing concerns of pain and harm among individuals with low back pain. Our games have two distinct advantages. First, within this video game environment, visual feedback can be altered by changing the feedback gain of a given movement (e.g., the magnitude of a given joint movement could appear on screen as either larger or smaller than the actual movement). Thus, gain manipulation will result in progressively larger amounts of lumbar spine flexion during game play. Second, video games are potent distractors that can reduce attention to pain.


Recruitment information / eligibility

Status Completed
Enrollment 159
Est. completion date October 14, 2023
Est. primary completion date October 14, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - 18-60 years of age - Low back pain that has been ongoing for at least half the days in the last 6 months - Average pain intensity of greater than 3 over the past week on a 0-10 Numerical Rating Scale - Disability greater than 4 on Roland and Morris Disability Questionnaire - Agrees with statement "It is not really safe for a person with my back problem to be physically active" or Tampa Scale of Kinesiophobia score greater than 36 - Has sought care or consultation from a health care provider for back pain - Meets category 1, 2, or 3 on the Classification System of the Quebec Task Force on Spinal Disorders which reflects low back pain without neurological signs - Working proficiency in English Exclusion Criteria: - Has a personal history of the following neurological disorders: Alzheimers, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinsons, Neuropathy, Stroke, Seizures - Has a personal history of the following cardiorespiratory disorders: Congestive heart failure, heart attack in past 2 years - Has a personal history of the following musculoskeletal disorders: Rheumatoid Arthritis, Muscular Dystrophy, pathologic fractures of the spine, avascular necrosis or osteonecrosis, severe osteoarthritis - History of spine surgery or a hip arthroplasty - Has active cancer - Has a chronic disease that may restrict movement or preclude safe participation - Has used opioids within 30 days prior to study enrollment - Reports being pregnant, lactating, or that they anticipate becoming pregnant within 2-months - Reports pending litigation related to CLBP - Has current drug or alcohol use or dependence that, in the opinion of the PIs, would interfere with adherence to study requirements - Has significant visual impairment that would prevent virtual reality headset use - Has significant motion sickness that would prevent virtual reality headset use

Study Design


Intervention

Behavioral:
Experimental Group 1
Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).
Experimental Group 2
Participants will complete 18 intervention visits over 9 weeks with the number of sessions tapered across weeks (i.e., 3 sessions/week in weeks 1-3, 2 sessions/week in weeks 4-6, and 1 session/week in weeks 7-9).

Locations

Country Name City State
United States Virginia Commonwealth University Richmond Virginia

Sponsors (3)

Lead Sponsor Collaborator
Virginia Commonwealth University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Ohio University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in Emotional Functioning Life Fulfillment Scale, Center for Epidemiologic Studies - Depression, Profile of Mood States, Patient-Reported Outcomes Measurement Information System (Anxiety, Depression, Positive Affect, Meaning & Purpose) Baseline 1-, 6-, 12-, 24-, and 48-weeks post-treatment
Other Change in Pain Vulnerability Tampa Scale for Kinesiophobia, Pain Catastrophizing Scale Baseline 1-, 6-, 12-, 24-, and 48-weeks post-treatment
Other Change in Pain Resilience Pain Resilience Scale, Pain Self Efficacy Questionnaire Baseline 1-, 6-, 12-, 24-, and 48-weeks post-treatment
Other Participant's Perception of Change as Function of Intervention Patient Global Impression of Change 6-, 12-, 24-, and 48-weeks post-treatment
Other Change in Pain Interference with Physical Function Brief Pain Inventory, Roland Morris Disability Questionnaire Baseline, 1-, 6-, 12-, 24-, and 48-weeks post-treatment
Other Participant Evaluation of the Treatment Treatment Evaluation Inventory Baseline and 1-week post-treatment
Primary Change in Pain Numerical Pain Rating Score Baseline, 1-, 6-, 12-, 24-, and 48-weeks post-treatment
Primary Change in Disability Roland Morris Disability Questionnaire Baseline, 1-, 6-, 12-, 24-, and 48-weeks post-treatment
Secondary Change in Lumbar Spine Flexion Standardized Reaching Paradigm Baseline, 1-, 6-, 12-, 24-, and 48-weeks post-treatment
Secondary Change in Pain & Harm Expectancy Standardized Reaching Paradigm Baseline, 1-, 6-, 12-, 24-, and 48-weeks post-treatment
Secondary Change in Real World Activity Activity Monitor Baseline, 1-, 6-, 12-, 24-, and 48-weeks post-treatment
See also
  Status Clinical Trial Phase
Completed NCT03243084 - Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy N/A
Suspended NCT04735185 - Stem Cells vs. Steroids for Discogenic Back Pain N/A
Completed NCT03162952 - RAND Center of Excellence for the Study of Appropriateness of Care in CAM
Completed NCT03240146 - Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain N/A
Completed NCT05282589 - Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients N/A
Completed NCT03637998 - Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain N/A
Recruiting NCT02289170 - Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100) N/A
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Completed NCT02231554 - Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial N/A
Recruiting NCT02063503 - Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients N/A
Completed NCT01704677 - Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT01177241 - Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids N/A
Completed NCT01177254 - Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions N/A
Completed NCT01490905 - A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain Phase 4
Completed NCT01177280 - Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes N/A
Completed NCT00984815 - Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment Phase 3
Completed NCT00767806 - A Study for Patient With Chronic Low Back Pain Phase 3
Completed NCT00761150 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3
Completed NCT00763321 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3

External Links